Full-Time

Director/Senior Director

Corporate Counsel

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

51-200 employees

Develops genetic medicines for neurological diseases

No salary listed

Senior, Expert

Lexington, MA, USA

Hybrid role of minimum 3 days in our Lexington, MA office to promote engagement with the business.

Category
Legal
Contract Management
Legal & Compliance
Requirements
  • BA/BS and JD degree from accredited colleges or universities
  • Admitted to practice law in the Commonwealth of Massachusetts
  • Five to seven years working in the life sciences (can be combined law firm and in-house experience)
  • Experience in the full range of pre-clinical contracting
  • Securities law experience preferred or a desire to learn securities law for a public company
  • Employment law experience preferred or a desire to learn
Responsibilities
  • Actively leads and negotiates agreements with our customers, distributors, and suppliers, including collaboration and licensing agreements, strategic service agreements, material transfer agreements, and supplier and other procurement agreements.
  • Engages with Voyager collaborators and customers to ensure the success of therapeutic programs.
  • Ensures compliance with applicable securities regulations by preparation and review of SEC filings, including the company’s proxy statement, 10-Qs, 10-Ks, 8-Ks, earnings materials and other investor presentations.
  • Works collaboratively with Voyager R&D and G&A teams to support day-to-day and ad hoc business development transactions.
  • Reviews technical and logistical materials to support our program teams to ensure compliance with associated transactions.
  • Provide assistance to the Human Resources team on employee matters.
  • Hybrid role of minimum 3 days in our Lexington, MA office to promote engagement with the business.
Desired Qualifications
  • Experience in securities law preferred but not required and can be trained
  • Employment law experience preferred or a desire to learn

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like ALS. Their approach involves using a proprietary AAV (adeno-associated virus) capsid discovery platform, which allows for the delivery of genetic material directly to the brain through intravenous dosing. This method addresses the challenge of crossing the blood-brain barrier, which is crucial for effective treatment of brain-related conditions. Unlike many competitors, Voyager Therapeutics emphasizes collaboration with larger pharmaceutical companies to enhance their research and development efforts, which helps them accelerate the commercialization of their therapies. The company's goal is to create meaningful treatments that improve the lives of patients suffering from severe neurological disorders.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Electric pulse technology could enhance gene therapy delivery efficiency and reduce costs.
  • Collaboration with Novartis may accelerate innovation in SMA and neurological treatments.
  • GBA1 program with Neurocrine could lead to new Parkinson's treatments and milestone payments.

What critics are saying

  • Potential securities fraud investigation may impact investor confidence and stock prices.
  • Delays in Novartis collaboration could affect strategic goals and financial projections.
  • New CFO appointment may lead to strategic shifts affecting operations and investor relations.

What makes Voyager Therapeutics unique

  • Voyager focuses on CNS diseases with high unmet medical needs.
  • Their proprietary AAV capsid platform enables effective gene delivery across the blood-brain barrier.
  • Strong partnerships with Novartis and Neurocrine Biosciences enhance their R&D capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

8%

2 year growth

12%
DDW Online
Apr 3rd, 2025
Anti-tau antibody and gene therapy show potential in Alzheimer's

Voyager Therapeutics will share the new data from its two preclinical programmes for Alzheimer's disease (AD) at the 2025 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2025), taking place April 1-5, 2025, in Vienna.

Markets Gone Wild
Feb 25th, 2025
Pomerantz Law Firm Investigates Potential Lawsuit Against Voyager Therapeutics: What Does This Mean for Individual Investors?

In a recent press release dated February 25, 2025, Pomerantz LLP announced that it is investigating potential securities fraud claims on behalf of investors of Voyager Therapeutics, Inc. (Voyager or the Company).

Stock Titan
Feb 25th, 2025
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Additionally, Voyager will participate in the Stifel 2025 Virtual CNS Forum, featuring a fireside chat on March 19, 2025, at 11:00 a.m. ET.

SMA News Today
Jan 3rd, 2025
Top 10 SMA news stories of 2024

At the start of 2024, Voyager Therapeutics announced that it would collaborate with Novartis to discover and develop next-generation gene therapies for SMA and other neurologic conditions.

MarketBeat
Sep 24th, 2024
Great Point Partners LLC Invests $12.67 Million in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Great Point Partners LLC invests $12.67 million in Voyager Therapeutics, Inc. (NASDAQ:VYGR).